Brice P, Bastion Y, Divine M, Nedellec G, Ferrant A, Gabarre J, Reman O, Lepage E, Fermé C
HDJ d'Hematologie, Hôpital Saint-Louis, Paris, France.
Cancer. 1996 Sep 15;78(6):1293-9. doi: 10.1002/(SICI)1097-0142(19960915)78:6<1293::AID-CNCR18>3.0.CO;2-W.
Patients in the first relapse of Hodgkin's disease comprise a heterogeneous group regarding their primary treatment and their clinical characteristics. Because therapeutic options for these patients vary from radiotherapy to combined modality or high dose therapy, we wanted to identify the prognostic factors that would optimize the treatment choice among the different options available.
Patients (n = 187) who relapsed for the first time after the end of treatment were included. Characteristics at diagnosis were: male to female ratio: 1.5; Stage III and IV: 59%; B symptoms: 60%; and mediastinal involvement: 76%, bulky in 29%. Chemotherapy (27%) or combined modality (73%) was prescribed. Relapses occurred 3 to 192 months (median: 35 mos) after the end of treatment; for 39% this interval was < 12 months. Characteristics at relapse were: Stage III and IV: 59%; and B symptoms: 46%. At first relapse, treatment was conventional (chemo- and/or radiotherapy) in 44% and intensive (high dose therapy with stem-cell transplantation) in 56%. These regimens led to 85% complete responses; and 15% were refractory.
The median follow-up after relapse was 31 months and the median time to second progression was 20 months. The median freedom from second failure (FF2F) was 44 months and the median survival was 72 months. All factors were analyzed for survival and FF2F. Patients given intensive treatment had more adverse prognostic factors at relapse (B symptoms, early relapse, and disseminated relapse). Multivariate analysis identified 2 significant prognostic factors: interval end of treatment-relapse < 12 months (< 10(-4)) and Stage III and IV at relapse (P = 0.0013). For patients with at least one adverse prognostic factor, high dose therapy gave the best survival results.
Using 2 simple prognostic factors, (interval end of treatment-relapse < 12 months and Stage III/IV at relapse), patients in first relapse of Hodgkin's disease can be classified into 3 significant prognostic groups in terms of survival and FF2F.
霍奇金淋巴瘤首次复发的患者在初始治疗及临床特征方面构成一个异质性群体。由于这些患者的治疗选择从放射治疗到联合治疗或高剂量治疗各不相同,我们希望确定能在现有不同治疗选择中优化治疗决策的预后因素。
纳入治疗结束后首次复发的患者(n = 187)。诊断时的特征为:男女比例1.5;Ⅲ期和Ⅳ期:59%;有B症状:60%;纵隔受累:76%,其中29%为大包块。采用化疗(27%)或联合治疗(73%)。复发发生在治疗结束后3至192个月(中位数:35个月);39%的患者此间隔时间<12个月。复发时的特征为:Ⅲ期和Ⅳ期:59%;有B症状:46%。首次复发时,44%的患者接受传统治疗(化疗和/或放疗),56%的患者接受强化治疗(高剂量治疗联合干细胞移植)。这些治疗方案导致85%的患者完全缓解;15%的患者难治。
复发后的中位随访时间为31个月,至第二次进展的中位时间为20个月。无第二次失败的中位时间(FF2F)为44个月,中位生存期为72个月。对所有因素进行生存和FF2F分析。接受强化治疗的患者在复发时有更多不良预后因素(B症状、早期复发和播散性复发)。多因素分析确定了2个显著的预后因素:治疗结束至复发的间隔时间<12个月(<10⁻⁴)和复发时为Ⅲ期和Ⅳ期(P = 0.0013)。对于至少有一个不良预后因素的患者,高剂量治疗的生存结果最佳。
利用2个简单的预后因素(治疗结束至复发的间隔时间<12个月和复发时为Ⅲ/Ⅳ期),霍奇金淋巴瘤首次复发的患者在生存和FF2F方面可分为3个显著的预后组。